Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

Summary

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Timeline

Start

2020-06-15

Primary completion

2024-07-19

Completion

2025-04-22

Publications

• Guttman-Yassky E, Irvine AD, Gooderham M, Weidinger S, Spelman L, Silverberg JI, Crane H, ElMaraghy H, DeLuca-Carter L, Piruzeli MLB, Martimianaki G, Pierce E, Agell H, Thaci D. Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin). Dermatol Ther (Heidelb). 2026 Jun 19. doi: 10.1007/s13555-026-01810-1. Online ahead of print.
• Silverberg JI, Wollenberg A, Stein Gold L, Yosipovitch G, Lio P, Vestergaard C, Stander S, Carrascosa JM, Gallo G, Casillas M, Ding Y, Yang FE, Pierce E, Agell H, Del Rosso J. Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis. Clin Exp Dermatol. 2026 May 26;51(6):1012-1019. doi: 10.1093/ced/llaf490.
• Guttman-Yassky E, Weidinger S, Simpson EL, Gooderham M, Irvine AD, Spelman L, Silverberg JI, ElMaraghy H, DeLuca-Carter L, Piruzeli MLB, Hu C, Yang FE, Pierce E, Bardolet L, Thaci D. Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin). Dermatol Ther (Heidelb). 2025 Aug;15(8):2217-2232. doi: 10.1007/s13555-025-01452-9. Epub 2025 Jun 23.

Drugs

Indications